The CHAMPS trade show in Denver recently became a focal point for discussions about 7-hydroxymitragynine (7-OH), a potent alkaloid derived from kratom. Promoted by some as a potential alternative for managing opioid addiction, 7-OH has sparked both interest and concern within the industry.
While exhibitors like Modus Brand highlighted strong consumer demand for 7-OH products, such as gummies and capsules, others expressed caution. Adrian Campa of FS Distribution called the substance “dangerous,” citing insufficient research into its long-term effects. Similarly, Dana Saye of Pure Infinity Botanicals noted the lack of studies on 7-OH and opted to steer clear of the trend.
Despite concerns, proponents argue that 7-OH represents innovation in the kratom market. Brittany Warner of 7-OHMZ described it as a “better mouse trap,” while acknowledging the need for responsible self-regulation within the industry.
For more insights, visit SupplySide Supplement Journal.
